MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Daiichi Sankyo

< Previous 1 2 3 4 Next >
News headline image
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
News headline image
Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial
From Daiichi Sankyo
Via Business Wire
News headline image
ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors
From Daiichi Sankyo
Via Business Wire
News headline image
Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA
From Daiichi Sankyo
Via Business Wire
News headline image
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA
From Daiichi Sankyo
Via Business Wire
News headline image
Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials
From Daiichi Sankyo
Via Business Wire
News headline image
ENHERTU® Showed Clinically Meaningful and Durable Responses Across Multiple HER2 Expressing Tumor Types in DESTINY-PanTumor02 Phase 2 Trial
From Daiichi Sankyo
Via Business Wire
News headline image
TURALIO® New Dosing Regimen Now Available in the U.S. for Certain Patients with Tenosynovial Giant Cell Tumor
From Daiichi Sankyo
Via Business Wire
News headline image
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials
From Daiichi Sankyo
Via Business Wire
News headline image
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
From Daiichi Sankyo
Via Business Wire
News headline image
Data Across Daiichi Sankyo DXd ADC Portfolio at 2022 SABCS Demonstrates Bold Progress in Advancing Treatment for Patients with Breast Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
From Daiichi Sankyo
Via Business Wire
News headline image
ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMO
From Daiichi Sankyo
Via Business Wire
News headline image
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen
From Daiichi Sankyo
Via Business Wire
News headline image
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
From Daiichi Sankyo
Via Business Wire
News headline image
DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell Carcinoma
From Daiichi Sankyo
Via Business Wire
News headline image
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
From Daiichi Sankyo
Via Business Wire
News headline image
Daiichi Sankyo Showcases Bold Leadership in Oncology with Survival Improvements for Certain Patients with Cancer at ASCO and EHA
From Daiichi Sankyo
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story